Still calculating financial ratios manually?
Stop wasting time — let the computer do it!
Cyclerion Therapeutics, Inc. (CYCN) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
301 BINNEY STREET CAMBRIDGE, MA 02142 |
| State of Incorp. | MA |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2026 Q1 | 12/31/2025 Q4 | 9/30/2025 Q3 | 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 3,240 | 4,568 | 3,006 | 3,639 | 3,232 | 2,872 | |||
| Cash and cash equivalent | 3,240 | 4,568 | 3,006 | 3,639 | 3,232 | 2,872 | |||
| Receivables | 1,000 | 100 | 525 | 581 | 556 | 44 | |||
| Prepaid expense | 384 | 386 | 462 | 256 | 421 | 621 | |||
| Other current assets | 11 | 11 | 27 | 21 | 16 | 11 | |||
| Total current assets: | 4,635 | 5,065 | 4,020 | 4,497 | 4,225 | 3,548 | |||
| Noncurrent Assets | |||||||||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | |||||||||
| Long-term investments and receivables | 5,350 | 5,350 | 5,350 | 5,350 | 5,350 | 5,350 | |||
| Long-term investments | 5,350 | 5,350 | 5,350 | 5,350 | 5,350 | 5,350 | |||
| Total noncurrent assets: | 5,350 | 5,350 | 5,350 | 5,350 | 5,350 | 5,350 | |||
| TOTAL ASSETS: | 9,985 | 10,415 | 9,370 | 9,847 | 9,575 | 8,898 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 664 | 729 | 668 | 972 | 610 | 585 | |||
| Accounts payable | 508 | 480 | 462 | 483 | 390 | 304 | |||
| Accrued liabilities | 156 | 249 | 206 | 489 | 220 | 281 | |||
| Other undisclosed current liabilities | 236 | 148 | 132 | 95 | 115 | 115 | |||
| Total current liabilities: | 900 | 877 | 800 | 1,067 | 725 | 700 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 900 | 877 | 800 | 1,067 | 725 | 700 | |||
| Equity | |||||||||
| Equity, attributable to parent | 9,085 | 9,538 | 8,570 | 8,780 | 8,850 | 8,198 | |||
| Additional paid in capital | 280,105 | 279,759 | 277,815 | 277,701 | 276,342 | 276,220 | |||
| Accumulated deficit | (271,020) | (270,221) | (269,245) | (268,921) | (267,492) | (268,022) | |||
| Total equity: | 9,085 | 9,538 | 8,570 | 8,780 | 8,850 | 8,198 | |||
| TOTAL LIABILITIES AND EQUITY: | 9,985 | 10,415 | 9,370 | 9,847 | 9,575 | 8,898 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2026 Q1 | 12/31/2025 Q4 | 9/30/2025 Q3 | 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 1,025 | 875 | 93 | 81 | 1,806 | 194 | ||
| Gross profit: | 1,025 | 875 | 93 | 81 | 1,806 | 194 | ||
| Operating expenses | (1,863) | (1,881) | (1,765) | (1,538) | (1,304) | (1,322) | ||
| Operating income (loss): | (838) | (1,006) | (1,672) | (1,457) | 502 | (1,128) | ||
| Nonoperating income | 39 | 30 | 1,348 | 28 | 28 | 405 | ||
| Other nonoperating income | 39 | 30 | 31 | 28 | 28 | 42 | ||
| Net income (loss) available to common stockholders, basic: | (799) | (976) | (324) | (1,429) | 530 | (723) | ||
| Dilutive securities, effect on basic earnings per share | (32,656) | 785,533 | 799,800 | 829,645 | (23,056) | 873,715 | ||
| Net income (loss) available to common stockholders, diluted: | (33,455) | 784,557 | 799,476 | 828,216 | (22,526) | 872,992 | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2026 Q1 | 12/31/2025 Q4 | 9/30/2025 Q3 | 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (799) | (976) | (324) | (1,429) | 530 | (723) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (799) | (976) | (324) | (1,429) | 530 | (723) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.
An easy way to get professional financial analysis in one click
Load financial statements → click "Get report" → Your report is ready.
No financial analysis knowledge required!